Evidence map›Paper›PMID 19629719›Full record

ArticleGenetica2010

Target site selection by the mariner-like element, Mos1.

Gwénaelle Crénès, Corinne Moundras, Marie-Véronique Demattei, Yves Bigot, Agnès Petit, Sylvaine Renault

Abstract read
PubMed Publisher
In one paragraph

Article in Genetica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Target capture during Mos1 transposition.The Journal of biological chemistry · 2014
    Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gwénaelle CrénèsUniversité François Rabelais de Tours, GICC, Parc de Grandmont, 37200 Tours, France.
Corinne Moundras
Marie-Véronique Demattei
Yves Bigot
Agnès Petit
Sylvaine Renault

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The eukaryotic transposon Mos1 is a class-II transposable element that moves using a "cut-and-paste" mechanism in which the transposase is the only protein factor required. The formation of the excision complex is well documented, but the integration step has so far received less investigation. Like all mariner-like elements, Mos1 was thought to integrate into a TA dinucleotide without displaying any other target selection preferences. We set out to synthesize what is currently known about Mos1 insertion sites, and to define the characteristics of Mos1 insertion sequences in vitro and in vivo. Statistical analysis can be used to identify the TA dinucleotides that are non-randomly targeted for transposon integration. In vitro, no specific feature determining target choice other than the requirement for a TA dinucleotide has been identified. In vivo, data were obtained from two previously reported integration hotspots: the bacterial cat gene and the Caenorhabditis elegans rDNA locus. Analysis of these insertion sites revealed a preference for TA dinucleotides that are included in TATA or TA x TA motifs, or located within AT-rich regions. Analysis of the physical properties of sequences obtained in vitro and in vivo do not help to explain Mos1 integration preferences, suggesting that other characteristics must be involved in Mos1 target choice.

Indexed as

AnimalsBase SequenceCaenorhabditis elegansDNA-Binding ProteinsDNA, RibosomalDNA Transposable ElementsDrosophilaGenetic TechniquesGenetic VectorsModels, GeneticModels, StatisticalMolecular Sequence DataNucleotidesPlasmidsSequence Homology, Nucleic AcidTransposasesDNA-Binding ProteinsDNA, RibosomalDNA Transposable Elementsmariner transposasesNucleotidesTransposases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.